In 1677, a Dutch cloth merchant named Antonie van Leeuwenhoek peered through a handmade microscope at a drop of semen and saw tiny moving bodies he called “animalcules.” It was the first time a human being had seen a spermatozoon. The first documented case of sperm donation was still 113 years away — and several thousand years of ethical questions that we have still not fully resolved.
In 1784, the Italian scientist Lazzaro Spallanzani proved a fundamental point: sperm could be introduced artificially and fertilisation would occur. He began with frogs. Then he successfully fertilised a female dog. The publication caused a scandal in academic circles — not so much because of the method, but because the result was possible at all.
Six years later, in 1790, Scottish surgeon John Hunter applied the same logic to a human being. His patient’s husband suffered from hypospadias — a congenital condition that made natural conception difficult. Hunter introduced the husband’s sperm using a syringe. A pregnancy followed. This was the first documented case of human artificial insemination.
Hunter did not publish the result during his lifetime — he understood that society was not ready. The record of the procedure was found in his archives only after his death.
From the first successful insemination to the first sperm bank, almost 170 years passed. Technology outpaced ethics. We are still closing that gap.
The first commercial sperm bank opened in the United States in 1971. By then it was clear the technology worked — but there was no consensus on how to use it responsibly. How many children could one donor father? Should donors be anonymous? Does a child have the right to know their biological origins? These questions have been answered differently in different countries — and there is still no global agreement.
International bodies — the WHO, ESHRE (European Society of Human Reproduction and Embryology), and ASRM (American Society for Reproductive Medicine) — have spent fifty years building a consensus on basic principles. These do not carry the force of law in every jurisdiction, but they set the standard that quality clinics worldwide aim for.
A donor must understand what they are agreeing to — not in general terms, but specifically. A typical documentation package includes: a description of the procedure, a legal waiver of parental rights, information on the maximum number of families and children, conditions for research use of the biological material, and the right to withdraw consent before the sample is frozen.
Most European jurisdictions and the United Kingdom require a mandatory “cooling-off” period — 7 to 14 days between receiving the documents and signing them. This is not a formality: studies show that around a third of donors, upon receiving full information, change their decision or substantially revise the conditions.
The standard minimum: an infectious disease panel (HIV, Hepatitis B and C, syphilis, chlamydia), karyotype, and a semen analysis to WHO 2021 criteria (concentration ≥ 16 million/ml, progressive motility ≥ 30%, morphology ≥ 4% by Kruger criteria). In the EU, testing for CFTR mutations (cystic fibrosis) and FMR1 (fragile X syndrome) is mandatory.
Psychological testing looks different in different countries. In the UK, a mandatory interview and written report from a psychologist are required. In the US it is at the discretion of the bank, frequently conducted remotely using standardised questionnaires (MMPI-2, Beck Depression Inventory). In the EU and Australia it is often combined with group seminars and ethics lectures.
Screening is repeated every 3 to 6 months during active donation. A sample taken today will not be used immediately: most protocols require a quarantine of at least 6 months, with repeat testing of the donor before thawing.
Anonymity in sperm donation is one of the sharpest ethical debates of the last two decades. It was once the default. Today the picture has changed fundamentally.
The United Kingdom abolished anonymity in 2005: all children conceived from donor material have the right, upon turning 18, to request the personal details of their donor. Germany, the Netherlands, Sweden and around ten other EU countries have done the same. Spain retains anonymity but allows donors to voluntarily agree to disclosure of medical information.
The United States is an exception: anonymity is permitted at the federal level and many banks offer it as standard. But the situation is shifting. The rise of consumer DNA tests (AncestryDNA, 23andMe) has effectively destroyed anonymity in practice — children conceived from anonymous donors are finding biological fathers through shared databases. Several American banks have already moved to an open-donor model in response to this trend.
Anonymity as a legal concept is dying. A $99 DNA test has made it practically unenforceable — regardless of what any contract says.
Three models exist today: full anonymity (personal data is never disclosed), limited anonymity or identity-release (the child may request data upon reaching adulthood), and open donor (data is available immediately by mutual agreement).
Without limits, one popular donor could theoretically become the biological father of hundreds of children. This is not hypothetical: in the United States, where limits are not legislatively mandated, cases have been documented where a single donor fathered 150 or more children. Several such stories became public and prompted wide debate — including in Congress.
International recommendations from the WHO and ESHRE: no more than 25 families per donor. The UK sets the limit at 10 families, Germany at 12. In the US, the ASRM recommends 25 but this is not a legal requirement. In many states there is no legislative limit at all.
The practical control mechanism is centralised registries. In the UK, the HFEA registry tracks the use of every sample. In most European countries, equivalent national databases exist. In the US, inter-bank data sharing is voluntary.
The European standard: donors are reimbursed for documented direct costs — transport, meals, time. In most EU countries this is €40–60 per visit. The UK: £35–50. No payment for “quality” of sperm, no bonuses for a rare genetic profile.
The United States takes a fundamentally different approach. Donors receive $75–200 per visit or more, and some banks offer additional bonuses for repeat visits and “in-demand” characteristics. This is legal and openly described as compensation — but critics point out that this level of payment effectively turns donation into a professional activity rather than an altruistic one.
The dilemma is real: higher compensation attracts more donors, reducing shortages. But it may also attract people for whom money is the primary motivation — which raises questions about the quality of voluntariness.
A quality sperm bank should be accredited: ISO 15189, AABB or CAP depending on the jurisdiction. In the EU, certification under the EU Tissues and Cells Directive is mandatory, with inspections every 1–2 years. In the UK, the HFEA requires annual reporting that is publicly available: number of active donors, number of procedures, pregnancy rates.
Recent innovations: QR codes on samples allow recipients to access the collection date, storage period and the donor’s basic profile via a mobile app. Personal account portals show the real-time status of a sample. This is not marketing — it is a response to genuine demand: recipients want to see the chain of custody and understand exactly what is happening with the biological material.
The best-known case is that of Jan Kjærulf Olsen, a Danish sperm donor whose story became public in 2012. By researchers’ estimates, over the course of his donations he became the biological father of more than 100 children across several countries. Some of those children have since found each other through DNA tests. Cases of rare hereditary conditions have been identified among his descendants — conditions that would have been detected at the screening stage had proper protocols been in place.
This case exposed three systemic failures simultaneously: the absence of an international registry, weak national enforcement of limits, and inadequate genetic screening. Denmark tightened its regulation afterwards. But most countries in the world still have neither centralised registries nor mandatory limits.
Whole-genome sequencing of donors is the next frontier. Today, extended carrier screening (ECS) covers 300–400 genes. A full genome will provide an order of magnitude more information. But new questions will arise: what to do with data about predisposition to conditions with incomplete penetrance? How to prevent discrimination against donors on the basis of genetic profile?
AI in donor selection is already a reality at some banks. Algorithms match the genetic profiles of donor and recipient to minimise the risk of overlapping recessive mutations. This is useful. But the same algorithm could theoretically begin ranking donors by “desirability” — and that is a direct path to eugenics, just digital.
Technology always outpaces ethics. The job of regulators is to close that gap. The job of users is to ask the right questions.
Ethical sperm donation is not simply a set of medical procedures. It is a system of agreements between the donor, the recipient, the future child and society. Each of the six principles — consent, screening, anonymity, limits, compensation, transparency — protects one of those parties.
The gap between the best global standards and what happens in practice in most countries remains wide. But it is narrowing — largely because recipients and donor-conceived adults have begun asking questions that it was not previously considered appropriate to answer publicly.
Module 2 (Donor Selection & Genetics) contains a full checklist for basic and extended donor screening — including questions to ask the clinic and criteria for assessing accreditation. Verified ART clinics are available in the Partners section.
testing for carrier status of 280–400+ autosomal recessive conditions. Allows the identification of overlapping mutations between donor and recipient before conception.
the mandatory period between sperm collection and use (minimum 6 months under EU standards), during which the donor undergoes repeat infectious disease testing.
a donor who has agreed to disclosure of their personal details to the child upon reaching adulthood. The standard in the UK, Germany, the Netherlands, Sweden and several other countries.
the proportion of sperm cells with damaged DNA. Not detected by a standard semen analysis but affects the likelihood of live birth and miscarriage risk. Normal range: < 15%.
the gene whose mutations cause cystic fibrosis. Testing for CFTR carrier status is part of the mandatory donor screening panel in the EU.